VANCOUVER, Jan. 9 – Sirius Genomics, a developer of pharmacogenomic tests, announced today that it has signed a collaborative agreement with the United Kingdom Critical Care Genomics (UKCCG) Group. The agreement focuses on the continued development of Sirius’ pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and Company under the […]
Acquisition Would Enhance Sequenom’s Position in Cancer Genomics and Noninvasive Cancer Diagnostics SAN DIEGO–Sequenom, Inc. (NASDAQ:SQNM) announces that it has submitted a proposal to the Board of Directors of EXACT Sciences Corporation (NASDAQ:EXAS) to acquire all of the outstanding shares of common stock of EXACT Sciences in an all-stock transaction valued at approximately $41 million. […]
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
REHOVOT, Israel and JERSEY CITY, New Jersey, January 8 — Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today it has signed an exclusive distribution agreement with Teva Pharmaceutical Industries Ltd. Under the terms of the agreement Teva will offer Rosetta Genomics’ miRview(TM) tests in Israel and Turkey. The terms […]
NuGEN Technologies, Inc., a leader in nucleic acid sample preparation and Almac Diagnostics, provider of translational genomics-based solutions, announced today that Almac has added NuGEN Ovation® Systems to its gene expression profiling services, to address the challenges of analyzing valuable, irreplaceable clinical samples. In addition, Almac has also chosen to use Ovation Systems in its […]
St. Cloud, MN, (January 5, 2009) – MicroBioLogics, Inc. announced today that it has acquired the assets of Gibson Laboratories and established a new, wholly-owned subsidiary, Gibson Laboratories, LLC. Gibson Laboratories, based in Lexington, Kentucky, will retain key members of its management team who will report to MicroBioLogics CEO, Robert Coborn. Gibson Laboratories founder and […]
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it has signed an amended and restated master service agreement with GlaxoSmithKline, Ltd. (NYSE:GSK). This agreement extends the current agreement between the companies for a two-year period and names Response Genetics as preferred provider of […]
PLEASANTON, Calif., Dec. 31 — The United States Food & Drug Administration (FDA) today approved a new nucleic acid test from Roche to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay. The test, called the cobas TaqScreen MPX Test for use on the […]
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 — Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact […]
Celera Corporation (NASDAQ:CRA) and Abbott (NYSE:ABT) today announced a revision of the strategic alliance agreement between the two companies. Under a new distribution agreement, Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera. Under a second agreement, Celera will receive royalties on the sale of m2000™ reagents, instruments, service and related consumables, and […]
REHOVOT, Israel and JERSEY CITY, New Jersey and PHILADELPHIA, December 22 — Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its second diagnostic test, miRview(TM) mets. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. The test identifies 25 different tumor […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
